Independent Study Published In Clinical Breast Cancer Shows Activity Of Jaguar Health's Crofelemer For Neratinib-induced Diarrhea
Portfolio Pulse from Happy Mohamed
Jaguar Health, Inc. (NASDAQ:JAGX) announced positive results from an independent pilot phase 2 study of crofelemer for the management of neratinib-associated diarrhea in patients with HER2+ early-stage breast cancer. The study showed that crofelemer, Jaguar's FDA approved drug, may be effective for the management of neratinib-induced diarrhea. The results warrant further investigation of crofelemer for treatment of cancer therapy-related diarrhea (CTD). Top line results from the Company's ongoing phase 3 OnTarget clinical trial are expected in late October 2023.
August 07, 2023 | 12:44 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jaguar Health's crofelemer shows potential in managing neratinib-induced diarrhea in phase 2 study. Further investigation and phase 3 trial results could impact the company's stock positively.
The positive results from the phase 2 study of crofelemer for the management of neratinib-associated diarrhea could potentially boost Jaguar Health's stock. The anticipation of the phase 3 trial results, expected in late October 2023, could also have a positive impact on the stock in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100